The advantage of using positron emission tomography in drug research
- 30 June 1996
- journal article
- Published by Elsevier in Trends in Neurosciences
- Vol. 19 (6) , 211-214
- https://doi.org/10.1016/0166-2236(96)40002-9
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patientsPsychopharmacology, 1995
- Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in manPsychopharmacology, 1995
- Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and ClozapineArchives of General Psychiatry, 1992
- PET analysis of central [11 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effectsHuman Psychopharmacology: Clinical and Experimental, 1992
- The third dopamine receptor (D3) as a novel target for antipsychoticsBiochemical Pharmacology, 1992
- Distribution of remoxipride to the human brain and central D2‐ dopamine receptor binding examined in vivo by PETActa Psychiatrica Scandinavica, 1990
- Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levelsPsychopharmacology, 1989
- Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic DrugsArchives of General Psychiatry, 1988
- Quantitative Analysis of D2 Dopamine Receptor Binding in the Living Human Brain by PETScience, 1986
- Antipsychotic drug doses and neuroleptic/dopamine receptorsNature, 1976